trial

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCTId NCT02669758
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 281 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2018-06-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
281 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-01-20
Primary completion
2018-06-29
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
ALKS 3831

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

31 total
Little Rock, United StatesSpringdale, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesOrange, United StatesSan Diego, United StatesMiami, United StatesChicago, United StatesSt Louis, United StatesLas Vegas, United StatesMarlton, United States

Linked catalysts

1
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophre — primary completion2018-06-29

Facts & assertions

4 sourced
Enrollment
281
Phase
PHASE3
Primary Completion Date
2018-06-29
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 3831
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alkermes Medical Director, MD
person